Hints and tips:
Related Special Reports
Related Topics
...The US has much to offer across biotech, utilities, consumer companies and real estate,” said one Asia-based asset manager and adviser who spoke to GIC about its strategy....
...The senior official said several representatives from local governments, including Shenzhen and Guangzhou, have in recent months approached Middle Eastern funds to bolster investment in biotech, new energy...
...Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment....
...Shares in the rare disease and oncology specialist have drifted lower since the Covid-era biotech boom. Current levels hint at healthy buyout returns....
First example of artificial intelligence helping to accelerate diagnosis of diseases caused by genetic variants
...It is a far cry from the situation nine years ago when Malin, an Ireland-based life sciences investment company, raised €330mn in Dublin in one of Europe’s biggest biotech IPOs....
...Meanwhile in the US, biotech group Illumina on Sunday said it would divest from Grail, the cancer screening start-up it bought in 2021 for nearly $8bn, after the acquisition was blocked by the European Commission...
...The Financial Times Ltd and the authors are not responsible for any direct or indirect result arising from any reliance placed on replies, including any loss, and exclude liability to the full extent....
...“If you’re a garden-variety biotech start-up with little revenue, the auditing isn’t that complicated,” said Jay Ritter, an IPO expert at the University of Florida....
...The regulator said on Thursday it would grant full approval to lecanemab, now known by the brand name Leqembi, which was developed by Japanese drugmaker Eisai and US biotech Biogen....
Government seeks to win over pharma groups with new investments in genomics research and drug manufacturing
...Leqembi, which was jointly developed by Eisai and US biotech Biogen, is poised to become the first Alzheimer’s drug that can slow progression of the disease to win traditional approval by the US Food and...
...Earnings: The Chinese biotech company Sinovac will report first-quarter earnings....
...Beijing has not approved any mRNA vaccines, and the mass production of this type of technology is more complex than China’s existing inactivated shots made by Sinopharm and Sinovac, which produce a weaker...
...The US Food and Drug Administration in January approved lecanemab, a drug co-developed by Japanese drugmaker Eisai and US biotech Biogen, under an accelerated process....
...Some of them, such as CoWin BioSciences, a biotech company, have already received the green light to list....
...By contrast, the Shanghai-based Everest Medicines group made a deal to access the Canadian biotech company Providence Therapeutics’s mRNA vaccine candidate that involved a full tech transfer....
...Kelvin To, one of the HKU researchers, told the Financial Times that data on a third Sinovac dose “would be needed” to determine whether those who have had two Sinovac jabs should switch to other vaccines...
...The US biotech has been developing the treatment with Eisai of Japan....
...Analysts forecast the drug could generate sales worth up to $10bn a year, a prospect that would transform BioArctic, as well as Eisai and its partner on the drug, US biotech Biogen....
...Lecanemab, which was co-developed by Tokyo-based Eisai and US biotech Biogen, is a monoclonal antibody that acts by reducing the build-up of sticky plaques in the brain called beta-amyloid....
...And unless they’re high-tech or biotech or have the overwhelming majority of their operations in North America, most of these companies don’t really have the option of listing in the US; they would likely...
...But with vaccines that have already been in use for a year and a half, western biotech groups have a head start in adapting to new variants....
...Most Alzheimer’s drug candidates are not discovered by pharmaceutical companies but in academic labs and biotech businesses....
...São Paulo officials initially claimed CoronaVac, the vaccine produced by Sinovac, showed 78 per cent efficacy against mild to severe cases in local trials....
International Edition